Corresponding author. Applied Economic Department, School of Economics and Business, University of Granada, 18071. Granada. Spain Tel.: +0034958244261.
was read the article
array:24 [ "pii" => "S021391111500014X" "issn" => "02139111" "doi" => "10.1016/j.gaceta.2015.01.010" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "1089" "copyright" => "SESPAS" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2015;29:178-83" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3351 "formatos" => array:3 [ "EPUB" => 207 "HTML" => 2333 "PDF" => 811 ] ] "itemSiguiente" => array:19 [ "pii" => "S0213911115000072" "issn" => "02139111" "doi" => "10.1016/j.gaceta.2015.01.004" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "1083" "copyright" => "SESPAS" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2015;29:184-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5343 "formatos" => array:3 [ "EPUB" => 241 "HTML" => 4187 "PDF" => 915 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Tendencias en el consumo de alcohol en los adolescentes escolarizados españoles a lo largo de la primera década del siglo <span class="elsevierStyleSmallCaps">xxi</span>" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "184" "paginaFinal" => "189" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Alcohol consumption trends among Spanish school-aged adolescents in the first decade of the 21<span class="elsevierStyleSup">st</span> century" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 978 "Ancho" => 1632 "Tamanyo" => 74584 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Tendencias en haber tenido cuatro o más episodios de embriaguez en la vida en la población adolescente escolarizada española en 2002, 2006 y 2010, diferenciando por sexo y edad.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Inmaculada Sánchez-Queija, Carmen Moreno, Francisco Rivera, Pilar Ramos" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "Sánchez-Queija" ] 1 => array:2 [ "nombre" => "Carmen" "apellidos" => "Moreno" ] 2 => array:2 [ "nombre" => "Francisco" "apellidos" => "Rivera" ] 3 => array:2 [ "nombre" => "Pilar" "apellidos" => "Ramos" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213911115000072?idApp=WGSE" "url" => "/02139111/0000002900000003/v5_201507040026/S0213911115000072/v5_201507040026/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0213911115000199" "issn" => "02139111" "doi" => "10.1016/j.gaceta.2015.01.015" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "1094" "copyright" => "SESPAS" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2015;29:172-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4851 "formatos" => array:3 [ "EPUB" => 214 "HTML" => 3742 "PDF" => 895 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Carga de la mortalidad por diabetes mellitus en América Latina 2000-2011: los casos de Argentina, Chile, Colombia y México" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "172" "paginaFinal" => "177" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Burden of mortality due to diabetes mellitus in Latin America 2000-2011: the case of Argentina, Chile, Colombia, and Mexico" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2287 "Ancho" => 1617 "Tamanyo" => 237284 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Tasas ajustadas de mortalidad por diabetes mellitus según sexo. Argentina, Chile, Colombia y México, 2000-2011. Fuente: elaboración propia a partir de datos de INDEC (Argentina), INE (Chile), DANE (Colombia) e INEGI y Conapo (México).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marcela Agudelo-Botero, Claudio Alberto Dávila-Cervantes" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Marcela" "apellidos" => "Agudelo-Botero" ] 1 => array:2 [ "nombre" => "Claudio Alberto" "apellidos" => "Dávila-Cervantes" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213911115000199?idApp=WGSE" "url" => "/02139111/0000002900000003/v5_201507040026/S0213911115000199/v5_201507040026/es/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Productivity loss due to premature mortality caused by blood cancer: a study based on patients undergoing stem cell transplantation" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "178" "paginaFinal" => "183" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marta Ortega-Ortega, Juan Oliva-Moreno, Juan de Dios Jiménez-Aguilera, Antonio Romero-Aguilar, Ildefonso Espigado-Tocino" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Marta" "apellidos" => "Ortega-Ortega" "email" => array:1 [ 0 => "mortega2@ugr.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Juan" "apellidos" => "Oliva-Moreno" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Juan de Dios" "apellidos" => "Jiménez-Aguilera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Antonio" "apellidos" => "Romero-Aguilar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "Ildefonso" "apellidos" => "Espigado-Tocino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Applied Economic Department, University of Granada, Granada, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Economic Analysis Department and REDISSEC, University of Castilla La-Mancha, Castilla La-Mancha, Toledo, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Haematology Department, University Hospital Virgen de las Nieves, Granada, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Haematology Department, University Hospital Virgen del Rocío, University of Seville, Institute of Biomedicine of Seville, Seville, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author. Applied Economic Department, School of Economics and Business, University of Granada, 18071. Granada. Spain Tel.: +0034958244261." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Pérdidas de productividad por mortalidad prematura debido a una neoplasia hematológica: estudio basado en pacientes sometidos a un trasplante de células madre" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The attributable annual number of deaths worldwide due to cancer is predicted to rise from 7.6 million in 2008 to 13 million in 2030.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">1</span></a> The International Agency for Research of Cancer (IARC) estimated that 94.4 thousands deaths would occur in 2012 due to haematological malignancies (or blood cancer) in the 27 countries of the European Union (7.49% incidence rate).<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">2</span></a> Spain follows a similar trend, with blood cancer (taking into account leukaemia, lymphoma and multiple myeloma) being the fourth most common cause of death among all types of cancers<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">3</span></a> having caused an estimated 7.4 thousand deaths in 2012 which means a rate of 7.24%.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Because of this high mortality rate, the development and progressive evolution of haematopoietic stem cell transplantation (HSCT) in recent decades has been an important medical advance. HSCT has become an effective treatment for malignant and benign haematological diseases that could not be cured by other therapies, allowing for an increasing number of patients to become long-term survivors.<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">4,5</span></a> It is an essential part of the therapeutic strategy which is clinically recommended for blood cancer patients whose clinical condition indicates transplantation, are less than 65 years old (occasionally it can be higher) and are free of severe co-morbidities.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">4</span></a> In Spain, throughout Europe, its use has increased in a linear trend. In 2013, 2,945 transplantations were carried out in Spain in comparison with 1,974 transplantations in 2006.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">6</span></a> However, HSCT remains associated with significant morbidity and mortality rates<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">5</span></a> and it is one of the most expensive treatments of specialized medicine in Spain.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">7</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">International and national studies have assessed labour productivity losses due to mortality and morbidity for many cancers.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">8–13</span></a> Some of them have focused on specific types of cancer such as cervical, pancreatic, prostate and a large number on breast cancer.<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">14–17</span></a> However, to our knowledge, few studies have reported information about labour productivity losses due to blood cancer: one study was published two decades ago in Sweden, as part of a cost of illness analysis and took into account labour productivity losses due to morbidity and mortality in acute myeloid leukaemia,<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">18</span></a> also two articles concerning chronic lymphocytic leukaemia and lymphoma were recently published in Germany,<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">19,20</span></a> and in two articles about cancer, leukaemia and lymphoma were found to be amongst ten of the most costly cancers in terms of lost productivity due to premature cancer-related mortality.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">8,10</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">According to the national literature, just one Spanish study mentions “diseases of the blood and blood organs and disorders that affect immunity and the haematopoietic system” as an area of study and calculates losses in labour productivity due to death.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">13</span></a> Detailed information on different haematological diseases, stages or further treatments such as transplantation were not available in any national or international study. In addition, all of them follow the same methodology, the human capital method, and no specific study has been published on haematopoietic stem cell transplantation in spite of its increasing incidence in the society.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Our purpose is to provide detailed and useful information on affairs relating to one of the economic aspects of blood cancer. More specifically, our purpose is to estimate loss of labour productivity caused by the premature deaths of blood cancer patients who received stem cell transplantation.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Data</span><p id="par0030" class="elsevierStylePara elsevierViewall">Spain does not have a disaggregated national database containing details of treatments and mortality rates of malignant haematological diseases. Due to the lack of information, a primary database was created based on two hospital registries: Haematology Department of University Hospital of Virgen del Rocío (Seville) and Haematology Department of University Hospital of Virgen de las Nieves of Granada (Granada). The Clinical Research Ethics Committee of both health centres approved the study. Both hospitals are referenced in malignant haematological diseases in southeast and southwest in Spain, respectively. Our sample took into account the total adult population (over 16 years of age) in the provinces of Granada and Seville that received HSCT between 2006 and 2011 due to blood cancer and died before July 2012. Diagnoses of the patients were leukaemia, lymphoma, multiple myeloma, myelodisplastic syndrome and other malignant haematological diseases.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Study design</span><p id="par0035" class="elsevierStylePara elsevierViewall">We used standard statistics to describe the sample. Deaths were calculated in terms of years of potential life lost (YPLL) and years of potential productive life lost (YPPLL). YPLL was calculated following the methodological recommendations of the Spanish National Statistics Institute (INE) which considers premature death to be the years a person would have left to live if not for an early mortality which does not occur at the usual age of death for its collective.<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">21</span></a> The range of early mortality was considered to be between 1 to 69 years of age. Then, we transformed YPLL into YPPLL by estimating the number of total deaths during working age, in other words, between 16 and 65 years of age, being 65 the legal age of retirement at the time of the study in Spain. No discount rate was used for these calculations.</p><p id="par0040" class="elsevierStylePara elsevierViewall">The costs due to early mortality were calculated by applying the human capital (HC) method to the field of health. This approach points out that negative effects on the health of an individual might cause undesirable effects on their productivity at work and at home, and may result in a loss of leisure time not just for patients but also for caregivers. So, in the case of a worker who leaves the labour market due to premature mortality, the potential labour productivity towards the end of their working life will have been lost by society.<a class="elsevierStyleCrossRefs" href="#bib0285"><span class="elsevierStyleSup">22,23</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">The average earnings (wage) of a worker are considered a reasonable estimation of labour productivity.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">23</span></a> An incidence approach was used. We calculated the number of deaths of working-age individuals. The age limit for workers to remain in the labour market was set at 65 years. Once the age of individuals at the time of death and their expected gross lifetime wages were known, the present and future flow of productivity lost because of premature death could be calculated. The expected earnings and the employment rate were applied to each case, controlled by age and gender up to the predetermined limit of 65 years. Our calculations were performed based on the average gross wage figures contained in the latest Spanish Wage Structure Survey of the National Statistics Institute.<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">24</span></a> Employment data was obtained from the latest Labour Force Survey, also conducted by the National Statistics Institute, which defines the employment rate as the percentage of the population that is employed in relation to the total population of working age.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">25</span></a> The costs were actualized for 2009.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Our base case took into account the annual growth rate of labour productivity in Spain from 2001 to 2012 which was 0.9%,<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">26</span></a> and 4.3% as the annual discount rate, which is the mean profitability of 10-year government bonds in Spain from 2002 to 2012.<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">27</span></a> This is coherent with the recent methodological suggestions in economic evaluations.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">28</span></a> For the sensitivity analysis, we varied annual growth rates between 0%-2% and annual discount rates between 0%-6% as standard measures to facilitate comparison with international literature.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">28</span></a> We carried out an additional sensitivity analysis for estimating labour productivity losses using the friction cost (FC) method. According to this approach, workers who are forced to leave their jobs because of illness or mortality do not cause a large loss in productivity for society. The only productivity loss occurs while the post remains vacant. The authors estimated that this period could last between 2.5 and 3.5 months and it is called the “friction period”.<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">29,30</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><p id="par0055" class="elsevierStylePara elsevierViewall">179 out of 496 patients over 16 years of age underwent transplantations between 2006 and 2011 and had died as of July 2012. The average age at death was 45. The mean survival time from the day of the transplantation day was less than one year (303 days). 54.2% of the patients were male. The disease with the highest rate of mortality was leukaemia (41.3%). 45.3% were autologous transplantations, 90.5% were peripheral blood transplantations and 77.1% of patients received a myeloablative conditioning regimen. The descriptive characteristics of the study sample are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">When distributing the deaths by age and gender, we found most of the deaths happened in the 50–59 age group (27.37%) followed by the 40–49 age group (22.35%). However, detailed information shows that for patients under 30 years of age, the death rate of men was higher than that of women (16.50% vs. 9.76%). On the other hand, over 30 years of age, the death rate of men was lower than that of women, except for the 50-59 age group (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). As we can see in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>, leukaemia was the disease with the highest rate of mortality (41.34% of deaths) and the highest rate of death in men (46.39%). The YPLL and YPPLL was identified as 4,268 and 3,563 respectively (Table I in Appendix on-line).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">In our base case, we estimated €31.4 million as the cost of labour productivity lost due to premature mortality. The maximum and minimum values obtained in the sensitivity analysis ranged between €61.5 using 2% as the annual growth rate and 0% as the annual discount rate, and €24.7 million using 0% as the annual growth rate and 6% as the annual discount rate. The standard rate characterized by 1% annual growth rate and 3% as annual discount rate valued €36.2 million (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">The average potential production loss per person was €185,855, taking into account our base case. Our results show that 69.5% of the total productivity losses are generated by men (€21,823,126) and 30.5% by women (€9,586,397). Additionally, almost 60% of productivity losses are generated by people who die between 30 and 49 years of age, and most of them between 30 and 39 (33.7%), in spite of the fact that in our sample most people died between the ages of 50 and 59 (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>).</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0075" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a> shows the cost of lost labour productivity by diagnosis, which was divided into three haematological disease groups according to their incidence: leukaemia, lymphoma and other haematological malignant diseases. The highest losses were accounted for by leukaemia (€15,141,521) because it had the highest death rate. However, lymphoma accounted the highest losses per death (€212,944) despite having the smallest number of deaths. This is because the average age of death in patients with lymphoma was the lowest for both males and females in comparison with other diagnoses.</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">In a sensitivity analysis, the FC method showed labour productivity losses of €480,153 for society (€2,841 per person), assuming the friction period lasts 2.5 months. It rises to €672,214 (€3,977 per person) using 3.5 months as the friction period. The FC method shows 1.52% of the costs of those determined by the HC method (<a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a>).</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">The IARC projected an increased incidence of cancer in Europe of 32% beginning in the mid-80s.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">2</span></a> Haematological malignancies has been one of cancers with the biggest increases in incident rate. In 2012, 186.7 thousand new cases of blood cancer were estimated in the EU-27 and 14.9 thousand in Spain.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">2</span></a> The predictions for Spain are now to reach 17.2 thousand new cases in 2015.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">3</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">This increased incidence makes it necessary to study the costs associated with different treatments to discover the economic impact on society (direct costs, indirect costs and informal care costs). Particularly, the European Society for Medical Oncology concluded, after reviewing many international articles, that labour productivity costs accounted for more than two-thirds of the total costs of cancer.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">9</span></a> However, few studies have been published relating to non-health care costs in the haematologic area, even though stem cell transplantation is an essential part of the treatment for increasing survival rate of patients and one of the most expensive therapies in Spain<span class="elsevierStyleSup">7</span>. Our study partially fills the knowledge gap highlighted by many authors on non-health care costs in the haematologic area.<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">19,20,31,32</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">We examined the potential labour productivity loss that society could gain if the transplantations were effective enough to allow oncohaematologic patients to survive and continue working in the labour market. This subgroup of patients received the best available treatment according to the clinical protocol, but premature mortality and productivity losses are still high. We conclude that, in a sample of 179 transplanted patients, 3,563 years of potential productivity have been lost and that the productivity losses for society because of early death have reached €31.4 million. In other words, our findings suggest that society could save on average €185,855 per surviving patient if they could have a quality of life good enough to continue working in the labour market. 69.5% of the total labour productivity losses are accounted for by men. This is due to the incorporation of economic information such as labour force participation and wage rates into the estimates, which usually inflate male costs relative to female cost.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">8,10–12</span></a> People who die between 30 and 49 years of age and leukaemia patients generate the higher losses. In contrast, losses are smaller using the Friction Cost method, representing just the 1.52% of losses showed by the Human Capital method. There is no agreement about which method is the best and both have been criticized.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">33</span></a> Some authors consider that HC method overestimates the results,<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">29,30</span></a> however it is solidly grounded in neoclassical economic framework. In contrast, FC approach breaks basic axioms of economic theory due to the absence of a theoretical framework. This could possibly be one of the underlying reasons for the increased use of HC in applied studies, although there are other reasons that hamper the empirical application of the friction cost method.<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">34</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">According to the international literature, which follows the Human Capital method, blood cancer is one of the most costly cancers in terms of cost of lost productivity due to premature mortality. A recent article published by Hanly et al.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">8</span></a> estimated the premature mortality costs of the 10 most common cancers in Ireland. They estimated that the most costly cancer in males, was leukaemia (€426,247 per death) followed by non-Hodgkin's lymphoma in the third position (€385,480 per death). Non-Hodgkin's lymphoma was the third highest in females (€157,289 per death). Kim et al.<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">35</span></a> published a similar article studying the economic burden of cancer in Korea. Leukaemia was the second most costly cancer ($167,000 per death), Hodgkin's lymphoma was estimated at $157,000, non-Hodgkin's lymphoma at $128,000, and multiple myeloma at $89,000 per death. Bradley et al.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">10</span></a> estimated cancer-related productivity costs in US and they pointed out that Hodgkin's lymphoma was the second most expensive ($544,118 per death). Leukaemia was calculated at $240,387 and non-Hodgkin's lymphoma at $219,407 per death. Just two studies have focused on the estimation of loss labour productivity due to premature mortality associated with blood cancer, specifically in acute myeloid leukaemia in Sweden in 1994 and malignant lymphoma in Germany in 2000.<a class="elsevierStyleCrossRefs" href="#bib0265"><span class="elsevierStyleSup">18,19</span></a> Loss per patient could not be calculated because of the lack information in both articles about the number of deaths of people under 65 years of age. Costs are very different depending on the country, and these differences are due to the labour market conditions and wages. Also, variables, such as type of cancer, methodology used, age or gender, influence the results and make comparison between studies more difficult.<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">10,14,33</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Our results are in line with those reported by other national studies. Antoñanzas et al.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">12</span></a> concluded that labour productivity losses due to premature mortality are distributed in an unequal way by gender in oncologic patients, as they are higher in men. Their results show an average labour productivity loss per premature death due to cancer of €92,592 (prices actualized to the year 2003). In the same line, Oliva et al.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">13</span></a> estimated €90,550 per patient in 2011. However, their further study pointed out the differences in cost depending on the type of cancer.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">14</span></a> The losses were calculated as €69,332 and €52,486 per premature death in cervical and breast cancer, respectively. They also compared HC vs. FC methods, obtaining sharp differences between them. Just their first study took into account haematological diseases, estimating a total labour productivity loss of €189,828 per premature death.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">13</span></a> These results are totally in agreement with ours.</p><p id="par0110" class="elsevierStylePara elsevierViewall">Several limitations of our study should be noted. The first limitation is our limited population on transplanted patients. This means that our results could not be extrapolated to the total blood cancer population in working age. Future directives for research could focus on amplifying our analysis using other Spanish health centres’ registries to increase the external validity of the present study and also using non-transplanted patients to compare results. The second limitation is related to the estimated average survival time. Given the short study period for people who had transplantation during 2010 and 2011, there could be a possible bias due to deaths out of the observational period. However, it is expected to be small. Thirdly, given the complexity of modelling employment rates for an uncertain future and following other studies, current employment rates were used in our analysis. Finally, the Friction Cost method determines the friction period as 2.5 or 3.5 months, however this period could be longer or shorter depending on the economic cycle of each country and its market labour.<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">29,30,33</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Our study is unique because the collection of premature mortality data is novel, takes into account the total transplanted population with blood cancer in two provinces, fills the lack of knowledge due to limited public information in Spain and captures three important domains: diagnosis, gender and age. Thus, this is the first study to examine labour productivity loss in a subgroup of transplanted patients.</p><p id="par0120" class="elsevierStylePara elsevierViewall">As some authors have remarked, it is necessary to use a social perspective to gain in-depth knowledge of blood cancer treatment costs.<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">31,32</span></a> Our results provide new information about labour productivity losses due to premature mortality of blood cancer patients who received a stem cell transplantation and add useful information about economic dimension that is valuable to society and decision-makers. They could be useful for future cost of illness studies in order to complement their epidemiological information.<elsevierMultimedia ident="tb0005"></elsevierMultimedia></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Funding</span><p id="par0140" class="elsevierStylePara elsevierViewall">This study has no received financial support.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Contribution and authorship</span><p id="par0165" class="elsevierStylePara elsevierViewall">M. Ortega-Ortega was the principal researcher and took primary responsibility for the paper. She coordinated the work jointly with J. Oliva-Moreno and JD. Jiménez-Aguilera and they analyzed statistically the database. A. Romero-Aguilar, I. Espigado-Tocino and M. Ortega-Ortega participated in data collection, aggregation and quality control of the databases. All the results were discussed among the authors. M. Ortega-Ortega wrote the first draft of the manuscript and the rest of the authors helped in the successive reviews up to the final version. All the authors have approved the final version.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conflicts of interest</span><p id="par0145" class="elsevierStylePara elsevierViewall">The authors report no potential conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres529758" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec549783" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres529757" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec549782" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Data" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Study design" ] ] ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0050" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Contribution and authorship" ] 10 => array:2 [ "identificador" => "sec0080" "titulo" => "Conflicts of interest" ] 11 => array:2 [ "identificador" => "xack180585" "titulo" => "Acknowledgements" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2014-08-06" "fechaAceptado" => "2015-01-22" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec549783" "palabras" => array:6 [ 0 => "Indirect costs" 1 => "Labour productivity" 2 => "Cost of illness" 3 => "Premature death" 4 => "Haematological malignancies" 5 => "Haematopoietic cell transplantation" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec549782" "palabras" => array:6 [ 0 => "Costes indirectos" 1 => "Productividad laboral" 2 => "Coste de enfermedad" 3 => "Mortalidad prematura" 4 => "Enfermedades hematológicas malignas" 5 => "Trasplante de células hematopoyéticas" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Stem cell transplantation has been used for many years to treat haematological malignancies that could not be cured by other treatments. Despite this medical breakthrough, mortality rates remain high. Our purpose was to evaluate labour productivity losses associated with premature mortality due to blood cancer in recipients of stem cell transplantations.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We collected primary data from the clinical histories of blood cancer patients who had undergone stem cell transplantation between 2006 and 2011 in two Spanish hospitals. We carried out a descriptive analysis and calculated the years of potential life lost and years of potential productive life lost. Labour productivity losses due to premature mortality were estimated using the Human Capital method. An alternative approach, the Friction Cost method, was used as part of the sensitivity analysis.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Our findings suggest that, in a population of 179 transplanted and deceased patients, males and people who die between the ages of 30 and 49 years generate higher labour productivity losses. The estimated loss amounts to over €31.4 million using the Human Capital method (€480,152 using the Friction Cost method), which means an average of €185,855 per death. The highest labour productivity losses are produced by leukaemia. However, lymphoma generates the highest loss per death.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Further efforts are needed to reduce premature mortality in blood cancer patients undergoing transplantations and reduce economic losses.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducción</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Durante muchos años el trasplante de células madre se ha usado para tratar neoplasias hematológicas que no podrían haber sido curadas mediante otras terapias. A pesar de este avance médico, la ratio de mortalidad es aún elevada. Nuestro objetivo es evaluar las pérdidas de productividad laboral por mortalidad prematura debido a una neoplasia hematológica en receptores de trasplante de células madre.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se recogieron datos primarios de las historias clínicas de pacientes con neoplasia hematológica, trasplantados durante los años 2006 y 2011 en dos hospitales españoles. Se realizó un análisis descriptivo y se calcularon los años potenciales de vida y los años potenciales de vida laboral perdidos. Las pérdidas de productividad laboral se estimaron usando el método del Capital Humano. El método de los Costes de Fricción se empleó como parte del análisis de sensibilidad.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">En una población de 179 pacientes trasplantados y fallecidos, se dan mayores pérdidas de productividad laboral en varones y en personas de edades comprendidas entre los 30 y 49 años. La pérdida estimada está por encima de €31.4 millones usando el método del Capital Humano (€480,152 usando el método Costes Fricción), lo que significa una pérdida media de €185,855 por persona fallecida. Las mayores pérdidas globales son generadas por la leucemia. Sin embargo, el linfoma genera las mayores pérdidas por fallecimiento.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Mayores esfuerzos son necesarios para reducir la mortalidad prematura de pacientes trasplantados por neoplasia hematológica y reducir el impacto económico y social asociado a la misma.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0160" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0065" ] ] ] ] "multimedia" => array:8 [ 0 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Characteristics \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Number \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Rate (%) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Sample</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">179 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Age at transplantation (mean; s.d.</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>; <span class="elsevierStyleItalic">range)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">44; 13; 16–67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Age at death (mean; s.d.; range)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45; 13; 16–68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Survival days (mean; s.d.; range)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">303; 313; 1–1,811 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Gender</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Diagnosis</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Acute myeloid leukaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Acute lymphoid leukaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hodgkin lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Non-Hodgkin lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Multiple myeloma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Myelodisplastic Syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">HSCT</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a><span class="elsevierStyleItalic">according to the type of donor</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Autologous \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Related allogeneic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Non-related allogeneic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">HSCT according to the stem cell source</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Peripheral blood \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">162 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">90.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Umbilical cord \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Bone marrow \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">HSCT according to the conditioning regimen</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Myeloablative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">138 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Non-myeloablative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">More than one transplantation</span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Two HSCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Three HSCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853722.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">S.d.: Standard deviation</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">HSCT: Haematopoietic stem cell transplantation</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Characteristics of patients.</p>" ] ] 1 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Female</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Male</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Total</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Ages \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">≤ 19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7.22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.47 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">20–29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8.54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9.28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8.94 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">30–39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">23.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">18.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20.67 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">40–49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">23.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">21.65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">22.35 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">50–59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">24.39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">29.90 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">27.37 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">60–64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10.97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10.31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10.61 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">≥65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8.54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.59 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">100.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">100.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">179 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">100.00 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">Diagnosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Acute leukaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">35.37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">46.39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">41.34 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">24.74 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">26.26 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Other haematological malignancies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">36.58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28.87 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">32.40 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">179 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100.00 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853720.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Number of deaths by age group, diagnosis and gender.</p>" ] ] 2 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Annual Discount Rate</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Growth of Labour Productivity \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">0% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">3% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">4.3% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">6% \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">46,209,137 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">32,489,469 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28,613,914 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">24,712,273 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">0.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">52,450,125 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">35,966,116 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">31,409,524<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">26,856,795 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">53,063,463 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">36,252,708 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">31,617,805 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">26,994,025 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">61,533,245 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">40,762,003 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">35,164,776 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">29,656,030 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853718.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">HSCT: Haematopoietic stem cell transplantation</p>" ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Base case</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Labour productivity losses (€) due to premature deaths in blood cancer patients undergoing HSCT<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> for the year 2009. Human Capital method.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Age \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Female \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Male \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">≤ 19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">239,032 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,603,106 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,842,138 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">20-29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,716,844 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3,583,395 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5,300,239 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">30-39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3,967,202 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6,627,791 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10,594,993 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.73 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">40-49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2,547,146 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5,509,152 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8,056,299 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25.65 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">50-59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1,046,626 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3,311,696 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4,358,322 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13.88 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">60- 64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">69,547 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">187,986 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">257,533 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.82 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">≥ 65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">- \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9,586,397 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21,823,126 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31,409,524 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.000 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Total/person \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">128,819 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">232,161 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">185,855 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100.00 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853719.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">HSCT: Haematopoietic stem cell transplantation</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Labour productivity losses (€) due to premature deaths by age group and gender in blood cancer patients undergoing HSCT<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">a</span></a> for the year 2009. Human Capital method. Base case (0.9%, 4.3%).</p>" ] ] 4 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Number of deaths (under 65 years old) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Average female age of death (s.d.) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Average male age of death (s.d.)<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total productivity losses (€) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Total productivity losses/person (€) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Acute leukaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">74 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">44 (10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">41 (14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15,141,521 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">204,615 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">43 (12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">40 (13) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9,795,424 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">212,944 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Other haematological malignancies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">52 (14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">52 (12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6,472,579 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">132,093 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853721.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">S.d.: Standard deviation</p> <p class="elsevierStyleNotepara" id="npar0035"><span class="elsevierStyleSup">b</span> HSCT: Haematopoietic stem cell transplantation</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Labour productivity losses (€) due to premature mortality by diagnosis in blood cancer patients undergoing HSCT, for the year 2009. Human Capital method. Base case (0.9%, 4.3%).</p>" ] ] 5 => array:7 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Labour productivity losses (€) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Human Capital method. Base case (0.9%; 4.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31,409,524 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Friction Cost method (2.5 months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">480,152 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Friction Cost method (3.5 months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">672,214 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">FC<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">b</span></a> (2.5 months) vs. HC<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.52% \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab853723.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0040">HSCT: Haematopoietic stem cell transplantation</p>" ] 1 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0045">FC: Friction cost</p>" ] 2 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0050">HC: Human capital</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Sensitivity analysis of labour productivity losses (€) in blood cancer patients undergoing a HSCT<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> for the year 2009.</p>" ] ] 6 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.doc" "ficheroTamanyo" => 29184 ] ] 7 => array:5 [ "identificador" => "tb0005" "tipo" => "MULTIMEDIATEXTO" "mostrarFloat" => false "mostrarDisplay" => true "texto" => array:1 [ "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">What is known about subject?</span><p id="par0125" class="elsevierStylePara elsevierViewall">Annual number of deaths due to blood cancer is rising every year. However, many few international studies have explored in-depth labour productivity losses due to premature mortality and none of them have focused on further treatment as stem cell transplantation. We give primary information to the international and national literature.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">What does this study add to the literature?</span><p id="par0130" class="elsevierStylePara elsevierViewall">This paper gives further information on labour productivity losses due to premature mortality in Spanish blood cancer patients, specifically on patients undergoing stem cell transplantation as part of their treatment. These non-medical costs of blood cancer could be taking into account by policy-makers for future policies. These results are very useful for future Spanish and international cost of illness studies due to the primary and disaggregated data.</p></span></span>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:35 [ 0 => array:3 [ "identificador" => "bib0180" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "World Health Organization, editors. World Health Statistics 2012: A snapshot of global health. World Health Organization; 2012. [Accessed 20 June 2014]. Available in: <a href="http://www.who.int/gho/publications/world_health_statistics/2012/en">http://www.who.int/gho/publications/world_health_statistics/2012/en</a>." ] ] ] 1 => array:3 [ "identificador" => "bib0185" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Ferlay" 1 => "E. Steliarova-Foucher" 2 => "J. Lortet-Tieulent" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2012.12.027" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer." "fecha" => "2013" "volumen" => "49" "paginaInicial" => "1374" "paginaFinal" => "1403" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23485231" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0190" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sociedad Española de Oncología Médica, editors. Las cifras del cáncer en España 2014. Sociedad Española de Oncología Médica. 2014. [Accessed 30 December 2014]. Available in: <a href="http://fecma.vinagrero.es/documentos/Las_cifras_del_cancer_2014.pdf.%20Spanish">http://fecma.vinagrero.es/documentos/Las_cifras_del_cancer_2014.pdf. Spanish</a>." ] ] ] 3 => array:3 [ "identificador" => "bib0195" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Stem cell transplantation in Europe: trends and prospects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.S. Tan" 1 => "C.A. Uyl de-Groot" 2 => "P.C. Huijgens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2007.08.020" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer." "fecha" => "2007" "volumen" => "43" "paginaInicial" => "2359" "paginaFinal" => "2365" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17919900" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0200" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term survival and late deaths after allogeneic hematopoietic cell transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.R. Wingard" 1 => "N.S. Majhail" 2 => "R. Brazauskas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.33.7212" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol." "fecha" => "2011" "volumen" => "29" "paginaInicial" => "2230" "paginaFinal" => "2239" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21464398" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0205" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Organización Nacional de Trasplantes, editors. Trasplante de Progenitores Hematopoyéticos, 2013. Memoria de Actividad. ONT, 2013. [Accessed 30 December 2014]. Available in: <a href="http://www.ont.es/infesp/Memorias/Forms/AllItems.aspx.%20Spanish">http://www.ont.es/infesp/Memorias/Forms/AllItems.aspx. Spanish</a>." ] ] ] 6 => array:3 [ "identificador" => "bib0210" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ministerio de Sanidad, Servicios Sociales e Igualdad. Portal Estadístico del SNS. Informes CMBD. Estadísticos de referencia de los GRD. Principales indicadores de los 20 GRD AP de mayor coste. Año 2012. [Accessed 23 December 2014]. Avilable in: <a href="http://pestadistico.inteligenciadegestion.msssi.es/">http://pestadistico.inteligenciadegestion.msssi.es/</a>." ] ] ] 7 => array:3 [ "identificador" => "bib0215" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P. Hanly" 1 => "L. Sharp" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2407-14-224" "Revista" => array:6 [ "tituloSerie" => "BMC Cancer." "fecha" => "2014" "volumen" => "14" "paginaInicial" => "224" "paginaFinal" => "233" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24670067" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0220" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The burden and cost of cancer" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Society for Medical Oncology" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Oncol." "fecha" => "2007" "volumen" => "18" "numero" => "Supl 3" "paginaInicial" => "iii8" "paginaFinal" => "iii22" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0225" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Productivity costs of cancer mortality in the United States: 2000-2020" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.J. Bradley" 1 => "K.R. Yabroff" 2 => "B. Dahman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jnci/djn384" "Revista" => array:6 [ "tituloSerie" => "J Natl Cancer Inst." "fecha" => "2008" "volumen" => "100" "paginaInicial" => "1763" "paginaFinal" => "1770" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19066273" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0230" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic burden of cancer across EU: a population-based a cost analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Luengo-Fernandez" 1 => "J. Leal" 2 => "A. Gray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(13)70442-X" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol." "fecha" => "2013" "volumen" => "14" "paginaInicial" => "1165" "paginaFinal" => "1174" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24131614" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0235" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Costes directos e indirectos del cáncer en España" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F. Antoñanzas" 1 => "J. Oliva" 2 => "M. Velasco" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cuadernos Económicos del ICE." "fecha" => "2006" "volumen" => "72" "paginaInicial" => "281" "paginaFinal" => "309" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0240" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain's Economy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Oliva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10198-011-0344-9" "Revista" => array:6 [ "tituloSerie" => "Eur J Health Econ." "fecha" => "2012" "volumen" => "13" "paginaInicial" => "605" "paginaFinal" => "614" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21858534" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0245" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indirect costs of cervical and breast cancer in Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Oliva" 1 => "F. Lobo" 2 => "J. López-Bastida" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Health Econom." "fecha" => "2005" "volumen" => "6" "paginaInicial" => "309" "paginaFinal" => "313" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0250" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Tingstedt" 1 => "E. Andersson" 2 => "A. Flink" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00268-011-1208-2" "Revista" => array:6 [ "tituloSerie" => "World J Surg." "fecha" => "2011" "volumen" => "35" "paginaInicial" => "2298" "paginaFinal" => "2305" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21850604" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0255" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The burden of out-of-pocket and indirect costs of prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Jayadevappa" 1 => "J.S. Schwartz" 2 => "S. Chatre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/pros.21161" "Revista" => array:6 [ "tituloSerie" => "The prostate." "fecha" => "2010" "volumen" => "70" "paginaInicial" => "1255" "paginaFinal" => "1264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20658653" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0260" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indirect costs associated with metastatic breast cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Y. Wan" 1 => "X. Gao" 2 => "S. Mehta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3111/13696998.2013.826228" "Revista" => array:6 [ "tituloSerie" => "J Med Econ." "fecha" => "2013" "volumen" => "16" "paginaInicial" => "1169" "paginaFinal" => "1178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23866016" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0265" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The economic costs of acute myeloid leukemia in Sweden" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G.R. Tennvall" 1 => "U. Persson" 2 => "B. Nilsson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Technol Assess Health Care." "fecha" => "1994" "volumen" => "10" "paginaInicial" => "683" "paginaFinal" => "694" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7843888" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0270" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost of illness of malignant lymphoma in Germany" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Reis" 1 => "P. Ihle" 2 => "U. Paulus" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Cancer Care." "fecha" => "2006" "volumen" => "15" "paginaInicial" => "379" "paginaFinal" => "385" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0275" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost of illness and economic burden of chronic lymphocytic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.R. Blankart" 1 => "T. Taika Koch" 2 => "R. Linder" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-1172-8-32" "Revista" => array:6 [ "tituloSerie" => "Orphanet J Rare Dis." "fecha" => "2013" "volumen" => "8" "paginaInicial" => "32" "paginaFinal" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23425552" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0280" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Instituto Nacional de Estadística (INE). Estadística de defunciones según la causa de muerte. Metodología. [Accessed 29 December 2014]. Available in: <a href="http://www.ine.es/daco/daco42/sanitarias/metodologia_00.pdf.%20Spanish">http://www.ine.es/daco/daco42/sanitarias/metodologia_00.pdf. Spanish</a>." ] ] ] 21 => array:3 [ "identificador" => "bib0285" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Human Capital" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.S. Becker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "1964" "editorial" => "Columbia University Press" "editorialLocalizacion" => "Chicago, USA" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0290" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "On the concept of health capital and the demand for health" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Grossman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Polit Econ." "fecha" => "1972" "volumen" => "80" "paginaInicial" => "223" "paginaFinal" => "255" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0295" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Instituto Nacional de Estadística (INE). Encuesta anual de estructura salarial (CNAE-2009). Serie 2008-2009. [Accessed 29 June 2014]. Available in: <a href="http://www.ine.es/jaxi/menu.do?type=pcaxis%26path=/t22/p133/cnae09/serie/%26file=pcaxis">http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t22/p133/cnae09/serie/&file=pcaxis</a>." ] ] ] 24 => array:3 [ "identificador" => "bib0300" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Instituto Nacional de Estadística (INE). Encuesta de población activa 2009. [Accessed 29 June 2014]. Available in: <a href="http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C%26cid=1254736176918%26menu=resultados%26idp=1254735976595">http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176918&menu=resultados&idp=1254735976595</a>." ] ] ] 25 => array:3 [ "identificador" => "bib0305" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Commision. EUROSTAT. Labour productivity, annual data. [Accessed 29 June 2014]. Available in: <a href="http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_aux_lp%26lang=en">http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_aux_lp⟨=en</a>." ] ] ] 26 => array:3 [ "identificador" => "bib0310" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Fernández P, Aguirreamalloa J, Linares P. Rentabilidad de los Fondos de Inversion en España, 2002-2012. (Mutual Funds in Spain, 2002-2012). [Accessed 29 June 2014]. Available in: <a href="http://ssrn.com/abstract=2220745">http://ssrn.com/abstract=2220745</a>." ] ] ] 27 => array:3 [ "identificador" => "bib0315" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. López-Bastida" 1 => "J. Oliva" 2 => "F. Antoñanzas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.gaceta.2009.07.011" "Revista" => array:6 [ "tituloSerie" => "Gac Sanit." "fecha" => "2010" "volumen" => "24" "paginaInicial" => "154" "paginaFinal" => "170" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19959258" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0320" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Towards a new approach for estimating indirect costs of disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.A. Koopmanschap" 1 => "B.M. Van Ineveld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Soc Sci Med." "fecha" => "1992" "volumen" => "34" "paginaInicial" => "1005" "paginaFinal" => "1010" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1631600" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0325" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The friction cost method for measuring indirect costs of disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.A. Koopmanschap" 1 => "F.F.H. Rutten" 2 => "B.M. van Ineveld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Health Econ." "fecha" => "1995" "volumen" => "14" "paginaInicial" => "171" "paginaFinal" => "189" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10154656" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0330" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Costs and cost-effectiveness of hematopoietic stem cell transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.M. Preussler" 1 => "E.M. Denzen" 2 => "N.S. Majhail" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bbmt.2012.04.001" "Revista" => array:6 [ "tituloSerie" => "Biol Blood Marrow Transplant." "fecha" => "2012" "volumen" => "18" "paginaInicial" => "1620" "paginaFinal" => "1628" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22484549" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0335" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic burden of acute myeloid leukaemia: a literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Redaelli" 1 => "M.F. Botteman" 2 => "J.M. Stephens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ctrv.2003.11.002" "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rev." "fecha" => "2004" "volumen" => "30" "paginaInicial" => "237" "paginaFinal" => "247" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15059647" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0340" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The friction cost method: a comment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Johannesson" 1 => "G. Karlsson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Health Econ." "fecha" => "1997" "volumen" => "16" "paginaInicial" => "249" "paginaFinal" => "255" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10173080" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0345" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimating productivity costs using the friction cost approach in practice: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Kigozi" 1 => "S. Jowett" 2 => "M. Lewis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Eur J Health Econ." "fecha" => "2014" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0350" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The economic burden of cancer in Korea in 2002" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.G. Kim" 1 => "M.I. Hahm" 2 => "K.S. Choi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Cancer Care." "fecha" => "2008" "volumen" => "17" "paginaInicial" => "136" "paginaFinal" => "144" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack180585" "titulo" => "Acknowledgements" "texto" => "<p id="par0150" class="elsevierStylePara elsevierViewall">The authors would like to thank the collaboration of the University Hospital Virgen de las Nieves (Granada, Spain) and University Hospital Virgen del Rocío (Seville, Spain), specially to health professionals of Haematology Department of both hospitals for their support in this study. The authors also thank F. Márquez Malaver for his contribution to improve quality of data.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/02139111/0000002900000003/v5_201507040026/S021391111500014X/v5_201507040026/en/main.assets" "Apartado" => array:4 [ "identificador" => "764" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02139111/0000002900000003/v5_201507040026/S021391111500014X/v5_201507040026/en/main.pdf?idApp=WGSE&text.app=https://gacetasanitaria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021391111500014X?idApp=WGSE" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 October | 70 | 34 | 104 |
2024 September | 83 | 29 | 112 |
2024 August | 93 | 36 | 129 |
2024 July | 59 | 28 | 87 |
2024 June | 50 | 25 | 75 |
2024 May | 58 | 35 | 93 |
2024 April | 51 | 18 | 69 |
2024 March | 49 | 24 | 73 |
2024 February | 41 | 39 | 80 |
2024 January | 40 | 26 | 66 |
2023 December | 36 | 13 | 49 |
2023 November | 48 | 17 | 65 |
2023 October | 49 | 18 | 67 |
2023 September | 39 | 16 | 55 |
2023 August | 44 | 12 | 56 |
2023 July | 49 | 32 | 81 |
2023 June | 47 | 15 | 62 |
2023 May | 60 | 18 | 78 |
2023 April | 51 | 25 | 76 |
2023 March | 68 | 40 | 108 |
2023 February | 41 | 20 | 61 |
2023 January | 33 | 28 | 61 |
2022 December | 61 | 28 | 89 |
2022 November | 78 | 60 | 138 |
2022 October | 57 | 44 | 101 |
2022 September | 28 | 32 | 60 |
2022 August | 53 | 74 | 127 |
2022 July | 47 | 46 | 93 |
2022 June | 42 | 39 | 81 |
2022 May | 46 | 40 | 86 |
2022 April | 50 | 50 | 100 |
2022 March | 45 | 67 | 112 |
2022 February | 41 | 41 | 82 |
2022 January | 45 | 52 | 97 |
2021 December | 43 | 49 | 92 |
2021 November | 55 | 46 | 101 |
2021 October | 56 | 72 | 128 |
2021 September | 42 | 54 | 96 |
2021 August | 37 | 44 | 81 |
2021 July | 33 | 32 | 65 |
2021 June | 45 | 40 | 85 |
2021 May | 42 | 45 | 87 |
2021 April | 116 | 82 | 198 |
2021 March | 74 | 57 | 131 |
2021 February | 40 | 27 | 67 |
2021 January | 31 | 34 | 65 |
2020 December | 41 | 38 | 79 |
2020 November | 38 | 27 | 65 |
2020 October | 27 | 18 | 45 |
2020 September | 31 | 29 | 60 |
2020 August | 28 | 29 | 57 |
2020 July | 30 | 28 | 58 |
2020 June | 39 | 27 | 66 |
2020 May | 27 | 22 | 49 |
2020 April | 43 | 28 | 71 |
2020 March | 28 | 21 | 49 |
2020 February | 43 | 34 | 77 |
2020 January | 32 | 17 | 49 |
2019 December | 44 | 39 | 83 |
2019 November | 41 | 20 | 61 |
2019 October | 47 | 21 | 68 |
2019 September | 33 | 15 | 48 |
2019 August | 38 | 20 | 58 |
2019 July | 55 | 17 | 72 |
2019 June | 41 | 26 | 67 |
2019 May | 41 | 27 | 68 |
2019 April | 47 | 15 | 62 |
2019 March | 35 | 27 | 62 |
2019 February | 81 | 23 | 104 |
2019 January | 37 | 23 | 60 |
2018 December | 42 | 15 | 57 |
2018 November | 115 | 23 | 138 |
2018 October | 178 | 31 | 209 |
2018 September | 173 | 15 | 188 |
2018 August | 85 | 11 | 96 |
2018 July | 114 | 17 | 131 |
2018 June | 135 | 21 | 156 |
2018 May | 143 | 15 | 158 |
2018 April | 42 | 12 | 54 |
2018 March | 47 | 13 | 60 |
2018 February | 28 | 11 | 39 |
2018 January | 29 | 13 | 42 |
2017 December | 41 | 8 | 49 |
2017 November | 50 | 13 | 63 |
2017 October | 39 | 13 | 52 |
2017 September | 31 | 14 | 45 |
2017 August | 22 | 10 | 32 |
2017 July | 30 | 20 | 50 |
2017 June | 35 | 10 | 45 |
2017 May | 48 | 18 | 66 |
2017 April | 48 | 17 | 65 |
2017 March | 33 | 24 | 57 |
2017 February | 7 | 7 | 14 |
2017 January | 24 | 10 | 34 |
2016 December | 57 | 16 | 73 |
2016 November | 59 | 22 | 81 |
2016 October | 46 | 12 | 58 |
2016 September | 26 | 8 | 34 |
2016 August | 0 | 11 | 11 |
2016 July | 0 | 13 | 13 |
2016 June | 1 | 12 | 13 |
2016 May | 0 | 10 | 10 |
2016 April | 0 | 15 | 15 |
2016 March | 0 | 8 | 8 |
2016 February | 2 | 11 | 13 |
2016 January | 2 | 0 | 2 |
2015 August | 1 | 1 | 2 |
2015 July | 2 | 0 | 2 |